Delivering solutions to the next generation of cardiovascular medicines
JB Flinders, Senior Director, CVMER, Operational Strategy and Planning and Peter Alfinito, Executive Director, CVMER, Operational Strategy and Planning February is American Heart Month, and we at...
View ArticleInnovative collaboration between Biomakers and Labcorp to provide greater...
In December 2022, Labcorp and Biomakers signed an agreement that will positively impact thousands of cancer patients in Latin America through greater access to diagnostic molecular profiling and...
View ArticleEnabling better access to kidney disease trials
March is National Kidney Month, and we at Labcorp are committed to improving the renal health of patients worldwide. The field of nephrology clinical research has been steadily adding new...
View ArticleProgram management services are now offered as part of Labcorp’s Preclinical...
When it comes to discoveries in oncology, cancer patients can’t wait, which means neither can you. At Labcorp Preclinical Oncology, we understand there are many steps, phases and regulations to wade...
View ArticleAlcohol-related liver disease: Inherent Challenges and Strategies for...
The association between excessive alcohol consumption and liver disease is well documented. In fact, the effect on alcohol consumption levels during the COVID-19 pandemic has more recently been...
View ArticleFaster access to biopesticide alternatives to conventional pesticides under...
There is pressure worldwide for better, faster access to biological alternatives to conventional crop protection chemicals (CPCs). The U.S. Environmental Protection Agency (EPA) is ahead of regions...
View ArticleWhat does a central lab do? 4 core services to know
Every clinical trial relies on data from its study participants to inform decisions regarding the safety and efficacy of a potential new treatment. Clinical trial sponsors rely on the data from...
View ArticleHow to de-risk OECD 443 studies through optimized dose level selections
The European Chemicals Agency (ECHA) recently conducted a review project regarding the design of the OECD 443 (Extended One-Generation Reproductive Toxicity Study, or EOGRTS). The project’s goal was to...
View ArticleTop considerations for developing a biomarker solution and CDx strategy
When it comes to designing clinical trials with expedience and efficiency, many drug developers are choosing biomarker-driven strategies for their investigational precision medicines. As key features...
View ArticleUK-REACH Planning
Introduction and U.K.’s exit from the EU On leaving the EU, EU-REACH legislation was copied over into UK-REACH as of 01 January 2020. Applying to only England, Wales and Scotland (collectively referred...
View Article
